2026 Q3 - tulosraportti
10 päivää sitten
‧1 t 3 min
3,75 DKK/osake
Viimeisin osinko
4,29%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 | ||
| 10 | ||
| 10 | ||
| 2 | ||
| 2 121 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·56 min sittenNovo Nordisk presents strong weight loss results with CagriSema in lower doses https://proinvestor.com/nyheder/novo-nordisk-prsenterer-strke-vgttabsresultater-med-cagrisema-i-lavere-doser?fbclid=IwY2xjawVlgPJleHRuA2FlbQIxMABwZG9mAWJyaWQRMUZpdG9RNE16eHdUYjB5cWFzcnRjBmFwcF9pZBAyMjIwMzkxNzg4MjAwODkyAAEf1qLkFNjGipGNBpoR5wlSWNhGUIdjz_SMlWhaGELeix9hJwHhwOiCKEviYEY_aem_FEszjpo8E3XeKhWH93SJYA
The new results from REDEFINE 9 are extremely interesting for Novo Nordisk. The most striking thing is that the lower doses of CagriSema delivered about 21 % weight loss after 68 weeks. 1,0 mg/1,0 mg: 21,0 % weight loss. 1,7 mg/1,7 mg: 20,7 % weight loss. Placebo: 2,0 % weight loss. This means that the lower dose actually performed at least as well as the higher dose. Why is this interesting for Novo Nordisk? 1. Possibility of lower doses and greater treatment flexibility. 2. Potentially better tolerability and fewer side effects. 3. Possibility of lower production costs. 4. A stronger competitive position against Eli Lilly. My assessment is that the results strengthen Novo Nordisk's long-term investment case. It is especially the 21 % weight loss at the low dose that is remarkable.
1 t sittenUpdate 14.11.2026: REDEFINE 9 trial showed CagriSema 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg produced estimated average weight loss of 20.7% and 21.0%, respectively, at 68 weeks, compared with 2.0% with placebo, in adults with overweight or obesity, if all patients stayed on treatment1 REDEFINE 9 is the first phase 3 trial to evaluate CagriSema, an investigational amylin analog and GLP-1 receptor agonist combination, at doses lower than 2.4 mg / 2.4 mg1,2 Plainsboro, New Jersey, US and Bagsværd, Denmark, 14 November 2026 – Today, Novo Nordisk announced primary results from the phase 3 REDEFINE 9 trial of investigational CagriSema, a fixed-dose combination of the long-acting amylin analogue cagrilintide and the GLP-1 receptor agonist semaglutide, in adults with overweight or obesity. REDEFINE 9 is the first phase 3 trial for weight management to evaluate CagriSema at doses lower than the maximum dose that has been evaluated in the REDEFINE clinical program, 2.4 mg / 2.4 mg.1 The results were presented at ObesityWeek® 2026 in Washington, DC, US, and simultaneously published in The Lancet Diabetes & Endocrinology.1,2 “Understanding how people respond to treatment across different doses is an important part of obesity research,” said Martin Holst Lange, executive vice president, chief scientific officer and head of Research & Development at Novo. “REDEFINE 9 studied each dose against its own placebo comparison over 68 weeks. The results add to our understanding of CagriSema across doses and, together with the broader REDEFINE program, inform how we continue to develop the combination of cagrilintide and semaglutide. We look forward to sharing these data with the scientific community at ObesityWeek®.” In REDEFINE 9, both doses of CagriSema produced significantly greater estimated average weight loss than placebo at week 68: 20.7% and 21.0%, respectively, compared with 2.0% with placebo (estimated treatment difference −18.8 and −19.0 percentage points; p<0.0001 for both), based on the efficacy estimand,* which reflects the treatment effect if all participants adhered to treatment.1 At both doses, a significantly higher proportion of adults achieved body weight reductions of at least 5%, 10%, 15% and 20% compared with placebo.1 Both CagriSema 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg also produced significantly greater reductions in abdominal fat, as measured by waist circumference, a confirmatory secondary endpoint (17.2 cm and 17.5 cm, respectively, compared with 3.6 cm with placebo; p<0.0001 for both).1 Based on the treatment regimen estimand,† estimated average weight loss at week 68 was 19.4% and 18.6% with CagriSema 1.7 mg /1.7 mg and 1.0 mg / 1.0 mg, respectively, compared with 4.6% with placebo (estimated treatment difference −14.7 and −13.9 percentage points; p<0.0001 for both), and 92.8% and 87.7%, respectively, achieved at least 5% body weight reduction, compared with 41.1% with placebo.1
·5 t sittenLucky for Ali that the dollar has risen so much, so she avoids having to come up with excuses for novos share price 🤣🤣🤣
- ·7 t sitten · MuokattuObesityWeek 2026 Dette skal vi især holde øje med hos Novo Nordisk. De kommende dage bliver interessante for Novo Nordisk, hvor selskabet præsenterer 26 abstracts på ObesityWeek 2026. Særligt tre områder er værd at følge: * Wegovy-pillen: Nye real-world-data, der kan give indblik i patienternes faktiske vægttab og behandlingsoplevelser. * CagriSema: Nye data om vægttab, livskvalitet og effekten af lavere doser. * Wegovy og food noise: Nye indsigter i, hvordan behandlingen påvirker appetit og konstante tanker om mad. Derudover kommer de fulde resultater fra STEP Young-studiet om behandling af fedme hos børn i alderen 6-11 år. Det store spørgsmål er, om de nye data kan styrke tilliden til Novos produkter og understøtte selskabets kommercielle position frem mod kommende internationale lanceringer.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
10 päivää sitten
‧1 t 3 min
3,75 DKK/osake
Viimeisin osinko
4,29%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·56 min sittenNovo Nordisk presents strong weight loss results with CagriSema in lower doses https://proinvestor.com/nyheder/novo-nordisk-prsenterer-strke-vgttabsresultater-med-cagrisema-i-lavere-doser?fbclid=IwY2xjawVlgPJleHRuA2FlbQIxMABwZG9mAWJyaWQRMUZpdG9RNE16eHdUYjB5cWFzcnRjBmFwcF9pZBAyMjIwMzkxNzg4MjAwODkyAAEf1qLkFNjGipGNBpoR5wlSWNhGUIdjz_SMlWhaGELeix9hJwHhwOiCKEviYEY_aem_FEszjpo8E3XeKhWH93SJYAThe new results from REDEFINE 9 are extremely interesting for Novo Nordisk. The most striking thing is that the lower doses of CagriSema delivered about 21 % weight loss after 68 weeks. 1,0 mg/1,0 mg: 21,0 % weight loss. 1,7 mg/1,7 mg: 20,7 % weight loss. Placebo: 2,0 % weight loss. This means that the lower dose actually performed at least as well as the higher dose. Why is this interesting for Novo Nordisk? 1. Possibility of lower doses and greater treatment flexibility. 2. Potentially better tolerability and fewer side effects. 3. Possibility of lower production costs. 4. A stronger competitive position against Eli Lilly. My assessment is that the results strengthen Novo Nordisk's long-term investment case. It is especially the 21 % weight loss at the low dose that is remarkable.
- 1 t sittenUpdate 14.11.2026: REDEFINE 9 trial showed CagriSema 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg produced estimated average weight loss of 20.7% and 21.0%, respectively, at 68 weeks, compared with 2.0% with placebo, in adults with overweight or obesity, if all patients stayed on treatment1 REDEFINE 9 is the first phase 3 trial to evaluate CagriSema, an investigational amylin analog and GLP-1 receptor agonist combination, at doses lower than 2.4 mg / 2.4 mg1,2 Plainsboro, New Jersey, US and Bagsværd, Denmark, 14 November 2026 – Today, Novo Nordisk announced primary results from the phase 3 REDEFINE 9 trial of investigational CagriSema, a fixed-dose combination of the long-acting amylin analogue cagrilintide and the GLP-1 receptor agonist semaglutide, in adults with overweight or obesity. REDEFINE 9 is the first phase 3 trial for weight management to evaluate CagriSema at doses lower than the maximum dose that has been evaluated in the REDEFINE clinical program, 2.4 mg / 2.4 mg.1 The results were presented at ObesityWeek® 2026 in Washington, DC, US, and simultaneously published in The Lancet Diabetes & Endocrinology.1,2 “Understanding how people respond to treatment across different doses is an important part of obesity research,” said Martin Holst Lange, executive vice president, chief scientific officer and head of Research & Development at Novo. “REDEFINE 9 studied each dose against its own placebo comparison over 68 weeks. The results add to our understanding of CagriSema across doses and, together with the broader REDEFINE program, inform how we continue to develop the combination of cagrilintide and semaglutide. We look forward to sharing these data with the scientific community at ObesityWeek®.” In REDEFINE 9, both doses of CagriSema produced significantly greater estimated average weight loss than placebo at week 68: 20.7% and 21.0%, respectively, compared with 2.0% with placebo (estimated treatment difference −18.8 and −19.0 percentage points; p<0.0001 for both), based on the efficacy estimand,* which reflects the treatment effect if all participants adhered to treatment.1 At both doses, a significantly higher proportion of adults achieved body weight reductions of at least 5%, 10%, 15% and 20% compared with placebo.1 Both CagriSema 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg also produced significantly greater reductions in abdominal fat, as measured by waist circumference, a confirmatory secondary endpoint (17.2 cm and 17.5 cm, respectively, compared with 3.6 cm with placebo; p<0.0001 for both).1 Based on the treatment regimen estimand,† estimated average weight loss at week 68 was 19.4% and 18.6% with CagriSema 1.7 mg /1.7 mg and 1.0 mg / 1.0 mg, respectively, compared with 4.6% with placebo (estimated treatment difference −14.7 and −13.9 percentage points; p<0.0001 for both), and 92.8% and 87.7%, respectively, achieved at least 5% body weight reduction, compared with 41.1% with placebo.1
- ·5 t sittenLucky for Ali that the dollar has risen so much, so she avoids having to come up with excuses for novos share price 🤣🤣🤣
- ·7 t sitten · MuokattuObesityWeek 2026 Dette skal vi især holde øje med hos Novo Nordisk. De kommende dage bliver interessante for Novo Nordisk, hvor selskabet præsenterer 26 abstracts på ObesityWeek 2026. Særligt tre områder er værd at følge: * Wegovy-pillen: Nye real-world-data, der kan give indblik i patienternes faktiske vægttab og behandlingsoplevelser. * CagriSema: Nye data om vægttab, livskvalitet og effekten af lavere doser. * Wegovy og food noise: Nye indsigter i, hvordan behandlingen påvirker appetit og konstante tanker om mad. Derudover kommer de fulde resultater fra STEP Young-studiet om behandling af fedme hos børn i alderen 6-11 år. Det store spørgsmål er, om de nye data kan styrke tilliden til Novos produkter og understøtte selskabets kommercielle position frem mod kommende internationale lanceringer.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 | ||
| 10 | ||
| 10 | ||
| 2 | ||
| 2 121 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
10 päivää sitten
‧1 t 3 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tuotteita joiden kohde-etuutena tämä arvopaperi
3,75 DKK/osake
Viimeisin osinko
4,29%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·56 min sittenNovo Nordisk presents strong weight loss results with CagriSema in lower doses https://proinvestor.com/nyheder/novo-nordisk-prsenterer-strke-vgttabsresultater-med-cagrisema-i-lavere-doser?fbclid=IwY2xjawVlgPJleHRuA2FlbQIxMABwZG9mAWJyaWQRMUZpdG9RNE16eHdUYjB5cWFzcnRjBmFwcF9pZBAyMjIwMzkxNzg4MjAwODkyAAEf1qLkFNjGipGNBpoR5wlSWNhGUIdjz_SMlWhaGELeix9hJwHhwOiCKEviYEY_aem_FEszjpo8E3XeKhWH93SJYAThe new results from REDEFINE 9 are extremely interesting for Novo Nordisk. The most striking thing is that the lower doses of CagriSema delivered about 21 % weight loss after 68 weeks. 1,0 mg/1,0 mg: 21,0 % weight loss. 1,7 mg/1,7 mg: 20,7 % weight loss. Placebo: 2,0 % weight loss. This means that the lower dose actually performed at least as well as the higher dose. Why is this interesting for Novo Nordisk? 1. Possibility of lower doses and greater treatment flexibility. 2. Potentially better tolerability and fewer side effects. 3. Possibility of lower production costs. 4. A stronger competitive position against Eli Lilly. My assessment is that the results strengthen Novo Nordisk's long-term investment case. It is especially the 21 % weight loss at the low dose that is remarkable.
- 1 t sittenUpdate 14.11.2026: REDEFINE 9 trial showed CagriSema 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg produced estimated average weight loss of 20.7% and 21.0%, respectively, at 68 weeks, compared with 2.0% with placebo, in adults with overweight or obesity, if all patients stayed on treatment1 REDEFINE 9 is the first phase 3 trial to evaluate CagriSema, an investigational amylin analog and GLP-1 receptor agonist combination, at doses lower than 2.4 mg / 2.4 mg1,2 Plainsboro, New Jersey, US and Bagsværd, Denmark, 14 November 2026 – Today, Novo Nordisk announced primary results from the phase 3 REDEFINE 9 trial of investigational CagriSema, a fixed-dose combination of the long-acting amylin analogue cagrilintide and the GLP-1 receptor agonist semaglutide, in adults with overweight or obesity. REDEFINE 9 is the first phase 3 trial for weight management to evaluate CagriSema at doses lower than the maximum dose that has been evaluated in the REDEFINE clinical program, 2.4 mg / 2.4 mg.1 The results were presented at ObesityWeek® 2026 in Washington, DC, US, and simultaneously published in The Lancet Diabetes & Endocrinology.1,2 “Understanding how people respond to treatment across different doses is an important part of obesity research,” said Martin Holst Lange, executive vice president, chief scientific officer and head of Research & Development at Novo. “REDEFINE 9 studied each dose against its own placebo comparison over 68 weeks. The results add to our understanding of CagriSema across doses and, together with the broader REDEFINE program, inform how we continue to develop the combination of cagrilintide and semaglutide. We look forward to sharing these data with the scientific community at ObesityWeek®.” In REDEFINE 9, both doses of CagriSema produced significantly greater estimated average weight loss than placebo at week 68: 20.7% and 21.0%, respectively, compared with 2.0% with placebo (estimated treatment difference −18.8 and −19.0 percentage points; p<0.0001 for both), based on the efficacy estimand,* which reflects the treatment effect if all participants adhered to treatment.1 At both doses, a significantly higher proportion of adults achieved body weight reductions of at least 5%, 10%, 15% and 20% compared with placebo.1 Both CagriSema 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg also produced significantly greater reductions in abdominal fat, as measured by waist circumference, a confirmatory secondary endpoint (17.2 cm and 17.5 cm, respectively, compared with 3.6 cm with placebo; p<0.0001 for both).1 Based on the treatment regimen estimand,† estimated average weight loss at week 68 was 19.4% and 18.6% with CagriSema 1.7 mg /1.7 mg and 1.0 mg / 1.0 mg, respectively, compared with 4.6% with placebo (estimated treatment difference −14.7 and −13.9 percentage points; p<0.0001 for both), and 92.8% and 87.7%, respectively, achieved at least 5% body weight reduction, compared with 41.1% with placebo.1
- ·5 t sittenLucky for Ali that the dollar has risen so much, so she avoids having to come up with excuses for novos share price 🤣🤣🤣
- ·7 t sitten · MuokattuObesityWeek 2026 Dette skal vi især holde øje med hos Novo Nordisk. De kommende dage bliver interessante for Novo Nordisk, hvor selskabet præsenterer 26 abstracts på ObesityWeek 2026. Særligt tre områder er værd at følge: * Wegovy-pillen: Nye real-world-data, der kan give indblik i patienternes faktiske vægttab og behandlingsoplevelser. * CagriSema: Nye data om vægttab, livskvalitet og effekten af lavere doser. * Wegovy og food noise: Nye indsigter i, hvordan behandlingen påvirker appetit og konstante tanker om mad. Derudover kommer de fulde resultater fra STEP Young-studiet om behandling af fedme hos børn i alderen 6-11 år. Det store spørgsmål er, om de nye data kan styrke tilliden til Novos produkter og understøtte selskabets kommercielle position frem mod kommende internationale lanceringer.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 | ||
| 10 | ||
| 10 | ||
| 2 | ||
| 2 121 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt